Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan.
Although the use of placebo in clinical trials of schizophrenia patients is controversial because of medical and ethical concerns, placebo-controlled clinical trials are commonly used in the licensing of new drugs.The objective of this study was to assess the attitudes toward placebo-controlled clin...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4658191?pdf=render |
| _version_ | 1819069925330780160 |
|---|---|
| author | Norio Sugawara Masamichi Ishioka Shoko Tsuchimine Koji Tsuruga Yasushi Sato Hanako Furukori Shuhei Kudo Tetsu Tomita Taku Nakagami Norio Yasui-Furukori |
| author_facet | Norio Sugawara Masamichi Ishioka Shoko Tsuchimine Koji Tsuruga Yasushi Sato Hanako Furukori Shuhei Kudo Tetsu Tomita Taku Nakagami Norio Yasui-Furukori |
| author_sort | Norio Sugawara |
| collection | DOAJ |
| description | Although the use of placebo in clinical trials of schizophrenia patients is controversial because of medical and ethical concerns, placebo-controlled clinical trials are commonly used in the licensing of new drugs.The objective of this study was to assess the attitudes toward placebo-controlled clinical trials among patients with schizophrenia in Japan.Using a cross-sectional design, we recruited patients (n = 251) aged 47.7±13.2 (mean±SD) with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder who were admitted to six psychiatric hospitals from December 2013 to March 2014. We employed a 14-item questionnaire specifically developed to survey patients' attitudes toward placebo-controlled clinical trials.The results indicated that 33% of the patients would be willing to participate in a placebo-controlled clinical trial. Expectations for improvement of disease, a guarantee of hospital treatment continuation, and encouragement by family or friends were associated with the willingness to participate in such trials, whereas a belief of additional time required for medical examinations was associated with non-participation.Fewer than half of the respondents stated that they would be willing to participate in placebo-controlled clinical trials. Therefore, interpreting the results from placebo-controlled clinical trials could be negatively affected by selection bias. |
| first_indexed | 2024-12-21T16:57:47Z |
| format | Article |
| id | doaj.art-001ee485aae1475585bbf324b05dcc15 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T16:57:47Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-001ee485aae1475585bbf324b05dcc152022-12-21T18:56:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011011e014335610.1371/journal.pone.0143356Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan.Norio SugawaraMasamichi IshiokaShoko TsuchimineKoji TsurugaYasushi SatoHanako FurukoriShuhei KudoTetsu TomitaTaku NakagamiNorio Yasui-FurukoriAlthough the use of placebo in clinical trials of schizophrenia patients is controversial because of medical and ethical concerns, placebo-controlled clinical trials are commonly used in the licensing of new drugs.The objective of this study was to assess the attitudes toward placebo-controlled clinical trials among patients with schizophrenia in Japan.Using a cross-sectional design, we recruited patients (n = 251) aged 47.7±13.2 (mean±SD) with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder who were admitted to six psychiatric hospitals from December 2013 to March 2014. We employed a 14-item questionnaire specifically developed to survey patients' attitudes toward placebo-controlled clinical trials.The results indicated that 33% of the patients would be willing to participate in a placebo-controlled clinical trial. Expectations for improvement of disease, a guarantee of hospital treatment continuation, and encouragement by family or friends were associated with the willingness to participate in such trials, whereas a belief of additional time required for medical examinations was associated with non-participation.Fewer than half of the respondents stated that they would be willing to participate in placebo-controlled clinical trials. Therefore, interpreting the results from placebo-controlled clinical trials could be negatively affected by selection bias.http://europepmc.org/articles/PMC4658191?pdf=render |
| spellingShingle | Norio Sugawara Masamichi Ishioka Shoko Tsuchimine Koji Tsuruga Yasushi Sato Hanako Furukori Shuhei Kudo Tetsu Tomita Taku Nakagami Norio Yasui-Furukori Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan. PLoS ONE |
| title | Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan. |
| title_full | Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan. |
| title_fullStr | Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan. |
| title_full_unstemmed | Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan. |
| title_short | Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in Japan. |
| title_sort | attitudes toward placebo controlled clinical trials of patients with schizophrenia in japan |
| url | http://europepmc.org/articles/PMC4658191?pdf=render |
| work_keys_str_mv | AT noriosugawara attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT masamichiishioka attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT shokotsuchimine attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT kojitsuruga attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT yasushisato attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT hanakofurukori attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT shuheikudo attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT tetsutomita attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT takunakagami attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan AT norioyasuifurukori attitudestowardplacebocontrolledclinicaltrialsofpatientswithschizophreniainjapan |